Effects of the anti-VEGF Monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed hodgkin lymphoma

Journal of Immunotherapy

Volumn 32, Issue 5, 2009, Pages 508-512

  Reiners, Katrin S ^a   Gossmann, Axel ^b   Von Strandmann, Elke Pogge ^a   Böll, Boris ^a   Engert, Andreas ^a   Borchmann, Peter ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b Hospital Merheim   (Germany)

Author keywords

Antiangiogenesis; Bevacizumab; Hodgkin lymphoma; VEGF

Indexed keywords

BEVACIZUMAB; CD30 ANTIGEN; FLUORODEOXYGLUCOSE; GEMCITABINE; THYMUS AND ACTIVATION REGULATED CHEMOKINE; VASCULOTROPIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD FLOW; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER RELAPSE; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG EFFECT; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUMOR VOLUME; TUMOR XENOGRAFT;

ADULT; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL GROWTH PROCESSES; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOTHERAPY; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67651166709     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181a25daf     Document Type: Article

References (15)

1. Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-.eld radiation in early-stage Hodgkin's disease. N Engl J Med. 2007;357:1916-1927.
2. Chau I, Harries M, Cunningham D, et al. Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. Br J Haematol. 2003;120:970-977.
3. Borchmann P, Schnell R, Diehl V, et al. New drugs in the treatment of Hodgkin's disease. Ann Oncol. 1998;9(suppl 5): S103-S108.
4. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28: 1779-1802.
5. Doussis-Anagnostopoulou IA, Talks KL, Turley H, et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed- Sternberg cells in Hodgkin's disease. J Pathol. 2002;197:677-683.
6. Agarwal B, Naresh KN, Re: Doussis-Anagnostopoulou IA, et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed- Sternberg cells in Hodgkin's disease. J Pathol. 2003;201:334-335.
7. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
8. Shames DM, Kuwatsuru R, Vexler V, et al. Measurement of capillary permeability to macromolecules by dynamic magnetic resonance imaging: a quantitative noninvasive technique. Magn Reson Med. 1993;29:616-622.
9. von Tresckow B, Kallen KJ, von Strandmann EP, et al. Depletion of cellular cholesterol and lipid rafts increases shedding of CD30. J Immunol. 2004;172:4324-4331.
10. Dias S, Hattori K, Heissig B, et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci U S A. 2001;98:10857-10862.
11. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333:328-335.
12. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10:145-147.
13. Weihrauch MR, Manzke O, Beyer M, et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res. 2005;65:5516-5519.
14. Zanotti R, Trolese A, Ambrosetti A, et al. Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma. Ann Oncol. 2002;13:1908-1914.
15. Rueda A, Olmos D, Villareal V, et al. Elevated vascular endothelial growth factor pretreatment levels are correlated with the tumor burden in Hodgkin lymphoma and continue to be elevated in prolonged complete remission. Clin Lymphoma Myeloma. 2007;7:400-405.